https://www.taxtmi.com/news?id=31052 Target-MRD combines tumor agnostic next generation sequencing with a customized tumor informed droplet digital PCR assay to provide personalised, high sensitivity blood monitoring for molecular residual disease in solid organ cancers, enabling earlier detection of circulating tumor related mutations and supporting timely clinical intervention. en-us Wed, 22 Jan 2025 11:01:03 +0530 Wed, 22 Jan 2025 11:01:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=31052 Target-MRD combines tumor agnostic next generation sequencing with a customized tumor informed droplet digital PCR assay to provide personalised, high sensitivity blood monitoring for molecular residual disease in solid organ cancers, enabling earlier detection of circulating tumor related mutations and supporting timely clinical intervention. News - Wed, 22 Jan 2025 11:01:03 +0530 https://www.taxtmi.com/news?id=31052